SynthesisFrontiers in oncology2026
CAR-HEMATOTOX score as a predictor of hematotoxicity, infection, and survival after CAR T-cell therapy in hematologic malignancies: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune effector cell-associated hematotoxicity (ICAHT) is a common and clinically important toxicity after chimeric antigen receptor (CAR) T-cell therapy. The CAR-HEMATOTOX score, also reported as CAR-HT, is a baseline risk score proposed to identify patients at higher risk of hematotoxicity and related adverse outcomes. Methods: We conducted a systematic search of PubMed, the Web of Science, and the Cochrane Library on June 19, 2026. Included studies compared high- and low-risk groups defined by the CAR-HEMATOTOX score after CAR T-cell therapy for hematologic malignancies and reported extractable data on hematologic toxicity, infection, survival, or other predefined clinical outcomes. Random-effects inverse-variance meta-analysis was performed only when at least three independent, clinically compatible estimates were available. Results: Twenty-three publications were included in the evidence inventory. For ICAHT, high risk was associated with higher odds (pooled OR 5.58, 95% CI 1.98 to 15.73; I²=60.8%). For overall survival (OS), high risk was associated with worse OS (pooled HR 3.36, 95% CI 2.20 to 5.11; I²=0.0%). For progression-free survival (PFS), high risk was associated with worse PFS (pooled HR 2.74, 95% CI 1.81 to 4.15; I²=32.3%). For severe infection, high-risk status was associated with higher odds (pooled OR 5.18, 95% CI 2.78 to 9.67; I²=37.8%). Exploratory analyses suggested higher early red blood cell and platelet transfusion requirements in high-risk patients, whereas severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were not significantly associated with high-risk status. Conclusion: A high CAR-HEMATOTOX score was associated with greater risk of ICAHT, higher odds of severe infection, and worse survival outcomes after CAR T-cell therapy for hematologic malignancies. These findings suggest that the CAR-HEMATOTOX score may be a clinically relevant risk-stratification marker, but the evidence remains observational and exploratory; standardized outcome definitions, prospective validation, and clearer handling of overlapping cohorts are needed before the score can be used as a stand-alone decision tool. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/view/CRD420261435303, identifier 420261435303.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.